Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Launched by M.D. ANDERSON CANCER CENTER · Jul 13, 2007

Keywords

ClinConnect Summary

This clinical trial is investigating how well a combination of chemotherapy drugs and a medication called nelarabine works in treating patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The goal is to understand both the effectiveness of these treatments and any side effects they may cause. The chemotherapy drugs used in this study are designed to fight cancer cells in various ways, such as killing them or preventing them from growing and spreading.

To participate in the trial, patients must have been diagnosed with T-cell ALL or lymphoblastic lymphoma and can be newly diagnosed or have had just one round of treatment that didn’t work. They should also meet certain health criteria, like having a specific level of liver and kidney function. This trial is currently looking for participants of all ages and genders. If someone joins, they can expect to receive a combination of different medications and will be closely monitored for how well the treatment is working and for any possible side effects. It's important to note that pregnant or nursing women cannot participate in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =\< 2 courses are also eligible
• • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3
• • Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable
• • Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)
• • Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 2.5 mg/dL is acceptable
• Exclusion Criteria:
• • Pregnant or nursing women